Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola

[11] Zhou L(2020)Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study Lancet 396 313-9

[12] Tong Y(2020)Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China Nat Med 26 1193-5

[13] Jin ZJ(2021)SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan Blood Transfus 19 181-9

[14] Dong X(2021)Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors Clin Infect Dis 72 249-53

[15] Yuan CY(2021)Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early months of the pandemic in Saudi Arabia Int J Infect Dis 104 452-7

[16] Dong YY(2020)SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020 Eurosurveillance 25 1-4

[17] Bin YY(2021)Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021 Res Sq 61 862-72

[18] Qin YY(2021)SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada Transfusion 82 79-82

[19] Zhou F(2020)Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors medRxiv 21 473-81

[20] Yu T(2021)SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study Lancet Infect Dis 16 1-12

[11] Zhou L(2020)Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study Lancet 396 313-9

[12] Tong Y(2020)Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China Nat Med 26 1193-5

[13] Jin ZJ(2021)SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan Blood Transfus 19 181-9

[14] Dong X(2021)Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors Clin Infect Dis 72 249-53

[15] Yuan CY(2021)Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early months of the pandemic in Saudi Arabia Int J Infect Dis 104 452-7

[16] Dong YY(2020)SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020 Eurosurveillance 25 1-4

[17] Bin YY(2021)Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021 Res Sq 61 862-72

[18] Qin YY(2021)SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada Transfusion 82 79-82

[19] Zhou F(2020)Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors medRxiv 21 473-81

[20] Yu T(2021)SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study Lancet Infect Dis 16 1-12